Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Getting breast implants was a mistake I live with every day. Why I’m sharing my story now, at 70, in pain and afraid. - 25 Critical Rules For Business Regulation Chiefs
- 3Japan deploys the military to counter a surge in bear attacks
- 4France honors the victims of the Paris attacks' night of terror 10 years on
- 5China bans storing cremated remains in empty 'bone ash apartments'
- 6 Travel Services for Colorful Get-aways: Pick Your Fantasy Escape
- NASA will bring space station crew home early after medical issue
- Monetary Wellness: Planning Tips for Independence from the rat race
- January full moon wows skywatchers with a striking 'Wolf Supermoon' (photos)
- Tech for Efficiency: Applications and Apparatuses to Accomplish More
- Figure out What Shift Differentials Mean for Your General Attendant Compensation
- Judge approves Purdue Pharma’s new $7B opioid settlement with the Sacklers
- EU waters down plans to end new petrol and diesel car sales by 2035
- Vote in favor of the bloom plan that adds a bit of excellence to your life!
